Remote Electric Neuromodulation Device for Acute Migraine Treatment Now Covered by VA
A Federal Supply Schedule (FSS) agreement has been signed with the Department of Veterans Affairs (VA) that enable veterans access to a therapeutic remote electric neuromodulation (REN) device (Nerivio; Theranica, Netanya, Israel). In multiple studies it has been shown that veterans are more likely to have migraines after 12-month deployments. Veterans have a 3 times higher rate of migraine than the general population.
"Nerivio has shown clinical efficacy for episodic and chronic migraine, both in clinical trials and real-world evidence analyses," said Jason Sico, MD, associate professor of Neurology and Internal Medicine in Yale School of Medicine. "Providing headache care to both veterans and nonveterans, it has been my experience that veterans tend to live with migraine and related headache disorders at higher rates than the general population. Making available effective treatments is extremely important. Drug free options like Nerivio resonate with the values and preferences of many veterans."
The REN device has been cleared by the Food and Drug Administration (FDA) for acute migraine treatment in people age 12 and up. The device is worn on the upper arm upon onset of a migraine attack and utilizes technology to activate native conditioned pain modulation mechanism in the brain to treat migraine pain and symptoms.
"As a US Navy veteran, I feel gratified to be able to provide veterans who suffer from migraine access to Nerivio", said Scott Szymanski, president Theranica US. "Veterans are one of the most at-risk populations for migraine and other headache disorders. We are committed to have Nerivio improve the quality of life of veterans receiving medical care within the VA system, as well as those that are making the transition back to civilian life."
"The VA is a role model for putting the well-being of its members at the highest priority," said Alon Ironi, chief executive and cofounder of Theranica. "We are also in the process of negotiating agreements with several commercial health insurance organizations. A significant amount of clinical data has solidified that Nerivio provides an effective and safe nonpharmacological alternative for treating migraine both in adults and adolescents, while also allowing patients and physicians to track the disease and understand how to best manage it through the Nerivio mobile application."